LUMOXITI is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Innate Pharma, Inc.. The primary component is Moxetumomab Pasudotox.
Product ID | 73380-4700_50a54d82-8f62-4e80-a35f-cd51a48bb0e5 |
NDC | 73380-4700 |
Product Type | Human Prescription Drug |
Proprietary Name | LUMOXITI |
Generic Name | Moxetumomab Pasudotox |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2020-05-15 |
Marketing Category | BLA / BLA |
Application Number | BLA761104 |
Labeler Name | Innate Pharma, Inc. |
Substance Name | MOXETUMOMAB PASUDOTOX |
Active Ingredient Strength | 1 mg/mL |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2020-05-15 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761104 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2020-05-15 |
NDC | Brand Name | Generic Name |
---|---|---|
0310-4700 | LUMOXITI | moxetumomab pasudotox |
73380-4700 | LUMOXITI | MOXETUMOMAB PASUDOTOX |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
LUMOXITI 87778486 5610169 Live/Registered |
INNATE PHARMA S.A. 2018-01-31 |